About this episode
The episode discusses the dynamics of life science angel investment with insights from industry experts.
In this episode of Denatured, you'll be hearing from Yaniv Sneor, founder of the Mid Atlantic Bio Angels and Alex Pederson, an investor at Mid Atlantic Bio Angels and partner at Alloy Bio Consulting. We discuss why a life sciences-only angel group matters, how they evaluate opportunities, and the importance of strong teams, capital efficiency and a realistic path to exit. Host Jennifer C. Smith-Parker , Director of Insights, BioSpace Guests Yaniv Sneor , Founder, Mid Atlantic Bio Angels Alex Pederson , Investor, Mid Atlantic Bio Angels & Partner, Alloy Bio Consulting Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
People in this episode
Host: Jennifer C. Smith-Parker
Guests: Yaniv Sneor, Alex Pederson
Topics covered
- life sciences
- angel investment
- capital efficiency
- team evaluation
- exit strategy
Keywords
- life science
- angel investment
- Mid Atlantic Bio Angels
- capital efficiency
- investment evaluation
Mentioned in this episode
Organizations: Mid Atlantic Bio Angels, Alloy Bio Consulting, BioSpace
More episodes of BioSpace
- Portugal, Spain and the new biotech frontier · June 10, 2026 · 21 min
- Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence · June 10, 2026 · 25 min
- Rethinking hair loss treatment · June 3, 2026 · 22 min
- ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck · June 3, 2026 · 27 min
- France’s biotech ecosystem: science, capital and scale · May 28, 2026 · 21 min
- Lilly wheels and deals, Moderna gets boost on hantavirus scare, ASCO excitement builds · May 27, 2026 · 25 min
Explore listener stats, chart rankings, contacts and more on the BioSpace podcast page.